Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Pancreatic cancer showdown: surgery first or chemo first?

NCT ID NCT06978322

Disease control Sponsor: Minia University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jul 14, 2026 · Updated 2 times

Summary

This completed study looked at whether giving chemotherapy before surgery (neoadjuvant chemo) helps people with resectable pancreatic cancer live longer compared to having surgery right away. Thirty patients took part. The main goal was to see which approach leads to better overall survival and cleaner surgical margins.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
chemotherapy (neoadjuvant)
What this could lead to
If chemo-first works better, it could become a new standard approach for resectable pancreatic cancer, improving survival and surgical success.
What could go wrong
This is a small, single-center trial with only 30 patients. Results may not apply broadly, and the benefit of neoadjuvant chemo is still unproven.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

50 people

The number who actually took part.

Started

Feb 2025

Finished

Feb 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

This prospective and retrospective study will be conducted on 30 patients with resectable pancreatic cancer.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Computed tomography (CT) with pancreatic protocol + vascular mapping * Histopathologically proven malignant by CT-guided or endoscopic ultrasound (EUS)-guided biopsy Resectable pancreatic cancer means no contact of the tumor with the Superior mesenteric artery, Celiac axis \& Common hepatic artery, and contact of the tumor but ≤90° contact with the superior mesenteric vein \& portal vein. Exclusion Criteria: * Borderline resectable \& locally advanced pancreatic cancer * Tumor at the tail of the pancreas. * Metastatic pancreatic cancer * Unfit patients for surgery.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Management are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

exocrine pancreatic carcinoma malignant pancreatic neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Management Neoadjuvant chemotherapy Resectable pancreatic cancer Surgery

Contacts and locations

Locations

  • Minia University

    Minya, Minya Governorate, 61611, Egypt

More trials for these conditions

Other studies related to the condition(s) this trial covers.